Physician profile
Natalie Munoz-Sievert
NPI 1609004050
$3,805.65
in general payments reported to CMS, 2019-2025
28 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $572 · 2021: $698 · 2022: $911 · 2023: $663 · 2024: $259 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,149 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,148.93 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $928.32 | 2019-2023 | |
| Millicent US INC | $275.56 | 2020-2025 | Intrarosa, Femlyv, Femring |
| Sumitomo Pharma America, INC. | $240.52 | 2023 | Myfembree |
| Exact Sciences Corporation | $209.62 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $204.96 | 2019-2025 | |
| Daiichi Sankyo INC. | $187.08 | 2020-2025 | Injectafer |
| Gynesonics, INC. | $183.82 | 2022 | |
| Myovant Sciences INC. | $183.25 | 2021-2022 | |
| Exeltis, USA INC. | $173.45 | 2019-2023 | Nuvessa |
| Mayne Pharma Commercial LLC | $162.87 | 2021-2025 | |
| Organon LLC | $112.08 | 2021-2025 | Nexplanon |
| Therapeuticsmd, INC. | $108.51 | 2019-2022 | |
| Hologic Sales and Service, LLC | $106.33 | 2019-2023 | Aptima, Thinprep 2000 Processor |
| Medical Device Business Services, INC. | $100.14 | 2020 | |
| Lupin INC. | $94.88 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $92.29 | 2020-2025 | Paragard T 380a |
| Mylan Pharmaceuticals INC. | $87.21 | 2019-2022 | |
| Myriad Women'S Health, INC. | $74.67 | 2023 | Myrisk |
| Allergan, INC. | $53.63 | 2019-2020 | |
| Astellas Pharma US INC | $51.79 | 2022-2025 | Veozah |
| Mission Pharmacal Company | $38.59 | 2019-2020 | |
| Sage Therapeutics, LLC | $24.97 | 2022 | |
| Duchesnay USA Incorporated | $24.48 | 2019 | |
| Agile Therapeutics, INC. | $21.79 | 2023 | Twirla |
| Amag Pharmaceuticals, INC. | $18.26 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.56 | 2019 | |
| Avanos Medical | $14.90 | 2019 | |
| Meditrina | $14.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Munoz-Sievert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.